Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Q2 Revenues Fall After Sale of Genomics Services Operations

This article has been updated to correct an error in reporting genomics services sales.


NEW YORK, Aug. 12 (GenomeWeb News) - Genome Therapeutics reported today a sharp drop in second quarter revenues, in part reflecting the loss of sales from the Waltham, Mass.-based company's recently divested genomics services business.


Second quarter revenues were $1.7 million, down from $6 million in the year-ago quarter. Genomics services sales fell to $253,000 from $4 million, while revenues from the company's core biopharmaceutical operations slipped to $1.5 million from $1.9 million.


Genome Therapeutics' second quarter R&D expenses dropped to $4.3 million

friom $8.3 million, a decline the company attributed to a reduction in early-stage discovery research.


The company net loss for the quarter was $13.9 million versus $8.3 million in the same period last year.


As of June 28, Genome Therapeutics had cash, cash equivalents, and marketable securities totalling roughly $27.9 million.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.